Phase 3 Brain Cancer Trial, Recruiting NCT03741673 Sponsor: M.D. Anderson Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 3 Brain Cancer Trial, Recruiting

NCT03741673
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The main brain tumour being treated must be no larger than 4 cm (for single-session treatment) or 7 cm (for multi-session treatment) before surgery
  • A person must be considered a suitable candidate for a type of targeted brain radiation (called SRS) within 30 days before or after surgical removal of the tumour, as confirmed by a doctor's assessment or a specialist brain tumour team review
  • A person must have a reasonably good level of physical functioning, as measured by standard medical scoring tools, within 30 days of joining the trial (confirm with trial site for exact score requirements)
  • A person must agree to be randomly assigned to a treatment group, confirmed by signing an approved consent form
  • There must be no signs on brain scans that the cancer has spread to the lining of the brain or spinal cord, as confirmed by a specialist radiologist review
  • A person must have a documented history of cancer (a confirmed cancer diagnosis on record)

Who may not be able to join:

  • People who have previously received any radiation treatment to the brain for any reason
  • People whose primary (original) cancer is small-cell lung cancer, lymphoma, leukaemia, or multiple myeloma
  • People who are pregnant or currently breastfeeding (this is because a contrast dye used in scans may carry risks during pregnancy)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Debra N Yeboa, M.D. Anderson Cancer Center

Phone: 713-563-2300

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
8 November 2018
Est. completion
31 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Leptomeningeal disease (LMD)-free rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov